Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP
NCT06079359
Recruiting
The primary purpose of this study is to evaluate the efficacy of ALXN1850 versus placebo on radiographic outcomes in pediatric participants with HPP who have not previously been treated with asfotase alfa.
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
04/25/2025
Locations: Research Site, Baltimore, Maryland +69 locations
Conditions: Hypophosphatasia
Register for Updates
Exposure Therapy Study In Adults With Eating Disorders
NCT06171711
Recruiting
The current proposal will evaluate the feasibility, acceptability, and preliminary efficacy of Exposure Therapy for anorexia nervosa (AN) spectrum disorders (Exp-AN), an innovative treatment rooted in principles of inhibitory learning. Exp-AN will target anxiety about both eating and weight gain by combining in vivo (i.e., in real life) and imaginal (i.e., mental) exposure in novel ways (e.g., eating a feared food while listening to a recording describing fears about weight gain).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/25/2025
Locations: 905 W Govener Rd, Hershey, Pennsylvania
Conditions: Eating Disorders, Anorexia Nervosa
Register for Updates
177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma
NCT06322576
Recruiting
This is a single arm trial with one Cohort for people with recurrent or metastatic adenoid cystic carcinoma that cannot be treated with surgery. 10 participants will be enrolled in Cohort 1 at Johns Hopkins and will undergo DCFPyL PET/CT and 177Lu-PSMA dosimetry imaging only (single tracer dose). A feasibility analysis of dosimetry will be performed after meeting the accrual goal of Cohort 1 to determine if the study will proceed into Cohort 2. If Cohort 2 proceeds, based on the dosimetry analy... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Adenoid Cystic Carcinoma
Register for Updates
Informing Pain Treatment Using Pharmacogenomic Analysis
NCT06511401
Recruiting
This is a randomized, prospective study to evaluate the effects of preemptive pharmacogenomic (PGx) testing on opioid dosing decisions/selections and pain score in cancer patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois
Conditions: Adult Patients Who Are Receiving Oncologic Care
Register for Updates
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
NCT06533059
Recruiting
The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Research Site, La Jolla, California +32 locations
Conditions: Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer, Advanced Solid Tumor
Register for Updates
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
NCT06586112
Recruiting
The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: * Does ESK-001 reduce the severity of people's psoriasis? * How safe is ESK-001 in people with moderate to severe plaque psoriasis? The study includes 2 comparators: a placebo control (a 'dummy' tablet that does not contain the medicine ESK-001 but looks just like it) and an active control (apremilast, which is a medicine approved to treat psorias... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Alliance Dermatology, Phoenix, Arizona +181 locations
Conditions: Plaque Psoriasis
Register for Updates
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06635148
Recruiting
The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
04/25/2025
Locations: Retina Associates Southwest PC, Tucson, Arizona +46 locations
Conditions: Geographic Atrophy, Macular Degeneration
Register for Updates
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
NCT06721156
Recruiting
Researchers want to learn if giving MK-1167 (the study medicine) along with acetylcholinesterase inhibitor (AChEI) therapy can improve symptoms of Alzheimer's disease dementia (AD dementia), such as memory and mental activity. AD dementia is the most common type of dementia. AChEI therapy is the standard treatment for AD dementia. The goals of this study are to learn: * If at least one dose level (amount) of MK-1167 works to improve a person's memory and thinking compared to a placebo * About... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
04/25/2025
Locations: Banner Alzheimer's Institute ( Site 0110), Phoenix, Arizona +49 locations
Conditions: Alzheimer Disease, Dementia
Register for Updates
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT06767514
Recruiting
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Clinical Study Site, Hot Springs, Arkansas +22 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
NCT06843447
Recruiting
Researchers are looking for other ways to treat relapsed high-grade serous ovarian cancer. Relapsed means the cancer came back after treatment. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells that cover the ovaries, the lining of the belly, or in the fallopian tubes. Standard treatment (usual treatment) for people with relapsed high-grade serous ovarian cancer may include: * Chemotherapy, which is a treatment that uses medicine to destroy... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: START Mountain Region ( Site 0008), West Valley City, Utah +3 locations
Conditions: Ovarian Cancer Recurrent
Register for Updates
Normal Values in Hearing and Balance Testing
NCT01629108
Recruiting
Background: - Researchers at the National Institutes of Health give many tests of hearing and balance. These tests can help detect problems that affect hearing or balance. It is important to know exactly how healthy people perform on each of these tests. This information will indicate when a test result is normal and when a test result shows a problem. Researchers also want to determine the best methods for each test. Objectives: - To test different types of hearing and balance tests, and col... Read More
Gender:
ALL
Ages:
Between 5 years and 80 years
Trial Updated:
04/25/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Healthy Volunteer
Register for Updates
DBS for Obsessive-Compulsive Disorder
NCT02773082
Recruiting
There are two primary approaches to the treatment of OCD, pharmacotherapy and cognitive behavior therapy (CBT). Lack of therapeutic success with one approach leads to trials of the alternative approach or a combination of the two. A rarely used third therapy approach, appropriate for only the most severely afflicted and treatment resistant patients, is neurosurgical ablation of certain brain regions involved in mood and anxiety. The neurosurgical ablation procedures are irreversible in nature, a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Zucker Hillside Hospital, Queens, New York
Conditions: Obsessive-Compulsive Disorder (OCD)
Register for Updates